Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review
Open Access
- 23 September 2024
- journal article
- review article
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 6) , S322-S331
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromesAmerican Journal of Hematology, 2022
- Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 studyThe Lancet Haematology, 2022
- Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemiaBiomedicine & Pharmacotherapy, 2022
- Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trialThe Lancet Haematology, 2022
- Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experienceLeukemia Research, 2022
- Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysisClinical and Experimental Medicine, 2022
- Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trialThe Lancet Haematology, 2021
- How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemiaLeukemia, 2019
- Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for useAmerican Journal of Hematology, 2018
- ‘Acute myeloid leukemia: a comprehensive review and 2016 update’Blood Cancer Journal, 2016